Turing Pharma
- All
- News
-
'Most Hated Man' Gets Seven Years In Jail For Defrauding Investors
- Saturday March 10, 2018
- World News | Agence France-Presse
Infamous "Pharma Bro" Martin Shkreli, once dubbed the most hated man in America for ratcheting up the price of an HIV drug, was sentenced to seven years prison Friday on charges of defrauding investors.
- www.ndtv.com
-
Turing Pharma Names Chairman To Replace Martin Shkreli As CEO
- Saturday December 19, 2015
- World News | Reuters
Martin Shkreli, the poster boy for prescription drug price increases who was arrested for securities fraud this week, has stepped down from his post as chief executive officer of Turing Pharmaceuticals Inc, the company said on Friday.
- www.ndtv.com
-
Martin Shkreli, the Bad Boy of Pharmaceuticals, Hits Back
- Monday December 7, 2015
- Business | Andrew Pollack and Julie Creswell, The New York Times
A former hedge fund manager, Shkreli drew the wrath of consumers, became a talking point in the presidential campaign and spurred federal and state inquiries as well as a dialogue about how and whether to control rising drug prices.
- www.ndtv.com/business
-
'Most Hated Man' Gets Seven Years In Jail For Defrauding Investors
- Saturday March 10, 2018
- World News | Agence France-Presse
Infamous "Pharma Bro" Martin Shkreli, once dubbed the most hated man in America for ratcheting up the price of an HIV drug, was sentenced to seven years prison Friday on charges of defrauding investors.
- www.ndtv.com
-
Turing Pharma Names Chairman To Replace Martin Shkreli As CEO
- Saturday December 19, 2015
- World News | Reuters
Martin Shkreli, the poster boy for prescription drug price increases who was arrested for securities fraud this week, has stepped down from his post as chief executive officer of Turing Pharmaceuticals Inc, the company said on Friday.
- www.ndtv.com
-
Martin Shkreli, the Bad Boy of Pharmaceuticals, Hits Back
- Monday December 7, 2015
- Business | Andrew Pollack and Julie Creswell, The New York Times
A former hedge fund manager, Shkreli drew the wrath of consumers, became a talking point in the presidential campaign and spurred federal and state inquiries as well as a dialogue about how and whether to control rising drug prices.
- www.ndtv.com/business